Overview

Anticoagulation After RFCA

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The anticoagulation therapy is needed when rhythm control strategy is applied in atrial fibrillation patients but adverse events such as major bleeding exist. This study aims to examine the prognostic inpact of the duration of anticoagulation after radiofrequency ablation of paroxismal atrial fibrillation in patients with low thromboembolic risk. Paroxismal atrial fibrillation patients with 0 or 1 CHADS2-Vasc score undergoing radiofrequency ablation is randomized into one month anticoagulation group and two months anticoagulation group after the procedure. Thromboembolic event and adverse event including major or minor bleeding would be compared.
Phase:
N/A
Details
Lead Sponsor:
Yong Seog Oh
Treatments:
Anticoagulants